We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis (EAP)

This treatment has been approved for sale to the public.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00989807
First Posted: October 6, 2009
Last Update Posted: December 13, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Gilead Sciences
October 2, 2009
October 6, 2009
December 13, 2012
 
Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis
This program is to provide expanded access to aztreonam lysine for inhalation (AZLI) prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
Not Provided
Expanded Access
Drug: Aztreonam lysine
Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
Not Provided
 
Approved for marketing
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT00989807
Gilead Sciences
Gilead Sciences
Not Provided
Not Provided
Gilead Sciences
October 2012